Clinical Trial Detail

NCT ID NCT01701674
Title Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Cyclophosphamide + Fludarabine

Ipilimumab

Aldesleukin

Age Groups: adult

No variant requirements are available.